INTRODUCTION: Surgery is first-line therapy for glioblastoma, and there is evidence that gross total resection is associated with improved survival. Gross total resection, however, is not always possible, and relationships among extent (percent) of resection (EOR), residual volume (RV), and survival are unknown. The goals were to evaluate whether there is an association between EOR and RV with survival and recurrence and to establish minimum EOR and maximum RV thresholds. METHODS: Adult patients who underwent primary glioblastoma surgery from 2007 to 2011 were retrospectively reviewed. Three-dimensional volumetric tumor measurements were made. Multivariate proportional hazards regression analysis was used to evaluate the relationship between EOR and RV with survival and recurrence. RESULTS: Of 259 patients, 203 (78%) died and 156 (60%) had tumor recurrence. The median survival and progression-free survival were 13.4 and 8.9 months, respectively. The median (interquartile range) pre- and postoperative tumor volumes were 32.2 (14.0-56.3) and 2.1 (0.0-7.9) cm(3), respectively. EOR was independently associated with survival (hazard ratio [HR], 0.995; 95% confidence interval [CI]: 0.990-0.998; P = .008) and recurrence (HR [95% CI], 0.992 [0.983-0.998], P = .005). The minimum EOR threshold for survival (P = .0006) and recurrence (P = .005) was 70%. RV was also associated with survival (HR [95% CI], 1.019 [1.006-1.030], P = .004) and recurrence (HR [95% CI], 1.024 [1.001-1.044], P = .03). The maximum RV threshold for survival (P = .01) and recurrence (P = .01) was 5 cm(3). CONCLUSION: This study shows for the first time that both EOR and RV are significantly associated with survival and recurrence, where the thresholds are 70% and 5 cm(3), respectively. These findings may help guide surgical and adjuvant therapies aimed at optimizing outcomes for glioblastoma patients.
INTRODUCTION: Surgery is first-line therapy for glioblastoma, and there is evidence that gross total resection is associated with improved survival. Gross total resection, however, is not always possible, and relationships among extent (percent) of resection (EOR), residual volume (RV), and survival are unknown. The goals were to evaluate whether there is an association between EOR and RV with survival and recurrence and to establish minimum EOR and maximum RV thresholds. METHODS: Adult patients who underwent primary glioblastoma surgery from 2007 to 2011 were retrospectively reviewed. Three-dimensional volumetric tumor measurements were made. Multivariate proportional hazards regression analysis was used to evaluate the relationship between EOR and RV with survival and recurrence. RESULTS: Of 259 patients, 203 (78%) died and 156 (60%) had tumor recurrence. The median survival and progression-free survival were 13.4 and 8.9 months, respectively. The median (interquartile range) pre- and postoperative tumor volumes were 32.2 (14.0-56.3) and 2.1 (0.0-7.9) cm(3), respectively. EOR was independently associated with survival (hazard ratio [HR], 0.995; 95% confidence interval [CI]: 0.990-0.998; P = .008) and recurrence (HR [95% CI], 0.992 [0.983-0.998], P = .005). The minimum EOR threshold for survival (P = .0006) and recurrence (P = .005) was 70%. RV was also associated with survival (HR [95% CI], 1.019 [1.006-1.030], P = .004) and recurrence (HR [95% CI], 1.024 [1.001-1.044], P = .03). The maximum RV threshold for survival (P = .01) and recurrence (P = .01) was 5 cm(3). CONCLUSION: This study shows for the first time that both EOR and RV are significantly associated with survival and recurrence, where the thresholds are 70% and 5 cm(3), respectively. These findings may help guide surgical and adjuvant therapies aimed at optimizing outcomes for glioblastomapatients.
Entities:
Keywords:
GBM; extent of resection; glioblastoma; residual; surgery; survival; volumetric
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Kaisorn L Chaichana; Hasan Zaidi; Courtney Pendleton; Matthew J McGirt; Rachel Grossman; Jon D Weingart; Alessandro Olivi; Alfredo Quiñones-Hinojosa; Henry Brem Journal: Neurol Res Date: 2011-09 Impact factor: 2.448
Authors: Kaisorn L Chaichana; Khan K Chaichana; Alessandro Olivi; Jon D Weingart; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2010-10-01 Impact factor: 5.115
Authors: Kaisorn L Chaichana; Tomas Garzon-Muvdi; Scott Parker; Jon D Weingart; Alessandro Olivi; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: Ann Surg Oncol Date: 2010-08-10 Impact factor: 5.344
Authors: Matthew J McGirt; Khoi D Than; Jon D Weingart; Kaisorn L Chaichana; Frank J Attenello; Alessandro Olivi; John Laterra; Lawrence R Kleinberg; Stuart A Grossman; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2009-03 Impact factor: 5.115
Authors: Matthew J McGirt; Debraj Mukherjee; Kaisorn L Chaichana; Khoi D Than; Jon D Weingart; Alfredo Quinones-Hinojosa Journal: Neurosurgery Date: 2009-09 Impact factor: 4.654
Authors: Karim ReFaey; Shashwat Tripathi; Adip G Bhargav; Sanjeet S Grewal; Erik H Middlebrooks; David S Sabsevitz; Mark Jentoft; Peter Brunner; Adela Wu; William O Tatum; Anthony Ritaccio; Kaisorn L Chaichana; Alfredo Quinones-Hinojosa Journal: J Neurooncol Date: 2020-06-10 Impact factor: 4.130
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Federico Pessina; Pierina Navarria; Luca Cozzi; Anna Maria Ascolese; Matteo Simonelli; Armando Santoro; Elena Clerici; Marco Rossi; Marta Scorsetti; Lorenzo Bello Journal: J Neurooncol Date: 2017-07-08 Impact factor: 4.130
Authors: Brian R Hirshman; Ali A Alattar; Sanjay Dhawan; Kathleen M Carley; Clark C Chen Journal: Acta Neurochir (Wien) Date: 2019-01-23 Impact factor: 2.216
Authors: Rafael De la Garza-Ramos; Panagiotis Kerezoudis; Rafael J Tamargo; Henry Brem; Judy Huang; Mohamad Bydon Journal: Clin Neurol Neurosurg Date: 2015-11-12 Impact factor: 1.876